Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Total Non-Current Liabilities (2016 - 2025)

Coherus Oncology's Total Non-Current Liabilities history spans 13 years, with the latest figure at $428.6 million for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities changed N/A year-over-year to $428.6 million; the TTM value through Sep 2025 reached $428.6 million, changed N/A, while the annual FY2024 figure was $551.2 million, 32.18% down from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $428.6 million at Coherus Oncology, up from $302.9 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $812.7 million in Q4 2023 and bottomed at $302.9 million in Q2 2025.
  • The 5-year median for Total Non-Current Liabilities is $590.7 million (2021), against an average of $597.8 million.
  • The largest annual shift saw Total Non-Current Liabilities soared 82.71% in 2021 before it tumbled 60.06% in 2025.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $580.9 million in 2021, then grew by 6.42% to $618.2 million in 2022, then soared by 31.48% to $812.7 million in 2023, then plummeted by 32.18% to $551.2 million in 2024, then fell by 22.23% to $428.6 million in 2025.
  • Per Business Quant, the three most recent readings for CHRS's Total Non-Current Liabilities are $428.6 million (Q3 2025), $302.9 million (Q2 2025), and $551.2 million (Q4 2024).